

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JBM (HEALTHCARE) LIMITED**

**健倍苗苗(保健)有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2161)**

### **POSITIVE PROFIT ALERT**

This announcement is made by JBM (Healthcare) Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board, the Group is expected to record an increase in the range of 110% to 120% in the consolidated profit attributable to Shareholders for the six months ended 30 September 2022 (“**Consolidated Profit**”) as compared to that for the six months ended 30 September 2021.

The increase in Consolidated Profit was primarily attributable to the easing of social distancing policies in Hong Kong which buttressed retail spending sentiment and a gradual recovery of the Group’s overall sales, resulting in a substantial increase in revenue for the six months ended 30 September 2022 alongside a financial subsidy from the government through the Employment Support Scheme. The trend of consumer-shift towards greater proactivity in managing their health and wellness, together with the aging population, improved living standards and the sedentary lifestyle, will continue to support the growth and are expected to benefit the Group’s business in the foreseeable future. The Group has been making sound progress on its cross-border e-commerce platform, which provides a fast expanding avenue for reaching out to those target prospects in the mainland China market.

As at the date of this announcement, the consolidated results of the Group for the six months ended 30 September 2022 have not yet been finalised. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board. Such information has not been reviewed and confirmed by the auditors of the Company, and may be subject to adjustments. Further details of the Group's performance will be disclosed in the interim results announcement of the Company for the six months ended 30 September 2022 in accordance with the Listing Rules, which is expected to be published on 25 November 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**JBM (Healthcare) Limited**  
**Wong Yat Wai, Patrick**  
*Executive Director and Chief Executive Officer*

Hong Kong, 2 November 2022

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek as the Chairman and non-executive Director, Mr. Wong Yat Wai, Patrick (also as Chief Executive Officer) as executive Director, Mr. Yim Chun Leung and Mr. Yeung Kwok Chun, Harry as non-executive Directors, and Mr. Chan Kam Chiu, Simon, Mr. Luk Ting Lung, Alan and Mr. Lau Shut Lee, Tony as independent non-executive Directors.*